Tagrisso-Chemotherapy Combo Improves Survival in EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (osimertinib) combined with chemotherapy has demonstrated a significant overall survival (OS) benefit in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), according to final results from the Phase III FLAURA2 trial. The study enrolled 557 patients globally and compared Tagrisso plus pemetrexed and platinum-based chemotherapy to Tagrisso alone. Participants received 80mg of Tagrisso daily, with pemetrexed and either cisplatin or carboplatin every three weeks for four cycles, followed by maintenance- Tagrisso and pemetrexed. The combination showed longer OS and confirmed earlier progression-free survival (PFS) benefits. While adverse events were more frequent with the combination, they were consistent with known chemotherapy profiles, and treatment discontinuations remained low. These results reinforce Tagrisso’s role as a cornerstone in EGFRm NSCLC therapy. Over 80 countries, including the US, EU, China, and Japan, have already approved the regimen based on FLAURA2 data. Additional findings will be presented at an upcoming medical meeting.

22-07-2025